Please login to the form below

Not currently logged in

Eisai and SFJ Pharma form partnership

Eisai has agreed a partnership with US-based SFJ Pharma in a bid to speed up development of its pipeline

Eisai has entered into a collaborative development agreement with SFJ Pharma, a wholly-owned subsidiary of SFJ Pharmaceuticals, in an effort to further accelerate the late-stage clinical development of its pipeline.

Eisai said the deal will effectively leverage internal resources, as well as build a new partnership scheme. Under the scheme, Eisai will accept funding from external parties to conduct phase III studies for promising new drug candidates in order to push forward with numerous development programmes simultaneously and as quickly as possible.

The Japanese pharmaceutical company has entered into a collaborative development agreement with SFJ to conduct phase III studies with E7080 (lenvatinib) in thyroid cancer. These late-stage studies will be conducted by Eisai and wholly funded by SFJ, with Eisai paying SFJ milestone payments if E7080 obtains regulatory approval. If the compound is approved, all commercial rights shall remain with Eisai.

Eisai has previously established a strategic collaboration with Quintiles, through which it has been advancing multiple candidate anticancer compounds for proof of concept studies.

7th September 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...